Author + information
- Valentina Kutyifa,
- Himabindu Vidula,
- Saadia Sherazi,
- Anna Papernov,
- Scott McNitt and
- Jeffrey Alexis
Data on the clinical significance of early hospital readmission in patients with continuous flow left ventricular assist device (LVAD) are limited. We aimed to assess incidence, predictors, and outcome of early hospital readmission in LVAD patients.
Hospital readmission or death was assessed within 90 days after hospital discharge in 163 patients with HeartMate II LVADs implanted between May 2008 and June 2014. Predictors of early readmission were evaluated using multivariable Cox models. Subsequent 1-year risk of mortality was assessed.
Hospital readmission or death rate was 44% within 90 days. Age at implantation (HR=1.03 per 1 year increase, p=0.02), diabetes (HR=2.19, p=0.03) and smoking at baseline (HR=2.06, p=0.03) predicted early hospital readmission, while a higher baseline body mass index was protective (HR=0.92 per each unit increase in BMI, p=0.003). One-year all-cause mortality was 19% in patients with hospital readmission compared to 1% with no early hospital readmission (HR=19.81, p=0.005). Mortality was the highest in patients with recurrent readmission (2+ readmission 35% vs. 1 readmission 10%, p<0.001, Figure) (HR 2+ readmission = 41.63, p<0.001, HR 1st readmission = 9.68, p=0.049).
In LVAD patients, there is a high incidence of early and recurrent hospital readmissions within 90 days, associated with an increased mortality. Targeted interventions to prevent early and recurrent hospital readmissions are warranted to improve outcomes.
Poster Area, South Hall A1
Saturday, April 02, 2016, 3:45 p.m.-4:30 p.m.
Session Title: Heart Failure and Cardiomyopathies: Surgical Approaches/LVADs
Abstract Category: 27. Heart Failure and Cardiomyopathies: Therapy
Presentation Number: 1137-084
- 2016 American College of Cardiology Foundation